<DOC>
	<DOCNO>NCT01636479</DOCNO>
	<brief_summary>Primary Objectives : - To determine safety maximum tolerate dose ( MTD ) SAR405838 characterization dose-limiting toxicity ( DLTs ) . - To assess biological activity patient dedifferentiate liposarcoma MTD cohort expansion . Secondary Objectives : - Pharmacokinetic ( PK ) profile SAR405838 . - Biomarkers association SAR405838 . - Anti-tumor activity response SAR405838 . - Food effect SAR405838 PK . - Compliance SAR405838 treatment . - Cytochrome P450 3A4/5 ( CYP3A4/5 ) activity .</brief_summary>
	<brief_title>Phase 1 Safety Testing SAR405838</brief_title>
	<detailed_description>Total duration study participation patient one month screening follow treatment precluded toxicity , noncompliance , progression , death .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis solid tumor effective standard treatment available . Patients lymphomas may enrol . For dose escalation , tumor type high biomarker prevalence without molecular confirmation biomarker status , tumor type molecular confirmation biomarker status ; For MTD cohort expansion , dedifferentiate liposarcoma include . Presence locally advance metastatic disease least one measurable lesion . Exclusion criterion : Age &lt; 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 1 . Life expectancy &lt; 12 week . Unstable brain leptomeningeal disease base history physical examination . Inadequate organ function , positive pregnancy test . Pregnancy breastfeed . Any anticancer drug therapy within 2 week ( 8 week mitomycin C nitrosoureas ) 5 halflives drug prior study treatment , whichever short , prior study treatment . Unwillingness , postmenopausal surgically sterile , abstain sexual intercourse employ effective barrier medical method contraception study drug administration followup period . Recent ( 3 month ) history acute pancreatitis . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>